Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HCV/HIV-PI

Financiado

Cerrado

The impact of HCV diversity on replication fitness and protease inhibitor sensit...

The impact of HCV diversity on replication fitness and protease inhibitor sensitivity in HIV infected patients with chronic HCV Hepatitis C virus (HCV) is a major cause of premature death due to cirrhosis and hepatocellular carcinoma in a large proportion of the world population (>25 million). Recently, advances in the development of new therapeutic compou... ver más

31/07/2010

HCIII

208K€

Presupuesto del proyecto: 208K€

Líder del proyecto

FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2010-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

HCIII

208.35K€ | Lider

Proyectos interesantes

SAF2014-52400-R

Medical Technol...

Data Science

Cerrado

ANTIVIRAL

Medical Technol...

Data Science

100K€ Cerrado

SAF2010-21617-C02-01

Medical Technol...

Data Science

121K€ Cerrado

SAF2013-44282-R

Medical Technol...

Data Science

61K€ Cerrado

SAF2009-10403

Medical Technol...

Data Science

121K€ Cerrado

BIO2010-15121

Medical Technol...

Data Science

36K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 208K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Hepatitis C virus (HCV) is a major cause of premature death due to cirrhosis and hepatocellular carcinoma in a large proportion of the world population (>25 million). Recently, advances in the development of new therapeutic compounds to treat HCV have revealed several potent inhibitors of the HCV serine protease, which have reached clinical trials. However HCV has a high genetic variability, not only between genotypes but also between quasispecies of an infected individual. In HIV coinfected patients the levels of complexity and diversity of the HCV protease gene variants and the resultant impact on HIV coinfection are unknown. The advent of HCV genotype 1b derived replicon systems has enabled measurement of HCV subgenomic RNA replication in a cell-based format and aided the development in the new therapeutic compounds. However these replicons are not representative of the genetic variability within the HCV genotypes, subtypes and quasispecies. In this project proposal we wish to clone HCV NS3 sequences derived from the sera of HIV infected patients with chronic HCV to address the impact of diversity on replication fitness and the drug sensitivity in a transient replication assay. The importance of HIV co-infection will also be investigated. The project will take place in the Center for the Study of Hepatitis C, New York, USA were the state of the art techniques are currently being used. In the returning phase the methodology and experience will be transferred to Europe at the Hospital Carlos III, Madrid, Spain an institute renown for its research in HIV and viral hepatitis co-infection. This project will help understanding the mechanism of HCV drug resistance and will provide relevant information for the design of new anti-HCV drugs

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores